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Plasma volume, the intravascular portion of the extracellular fluid volume, can be measured
using standard dilution techniques with radiolabeled tracer molecules. In healthy persons,
plasma volume remains relatively constant as a result of tight regulation by the complex
interaction between neurohormonal systems involved in sodium and water homeostasis.
Although chronic heart failure (CHF) is characterized by activation of many of these
neurohormonal systems, few studies have evaluated plasma volume in this condition under
treatment. Untreated edematous decompensated heart failure (HF) is associated with a
significant expansion of plasma volume. Patients with stable CHF, receiving conventional
therapy, appear to have a contracted plasma volume, a concept that is in contrast to the widely
held belief that CHF is associated with long-term hypervolemia. It is likely that significant
changes in plasma volume occur during intensification of medical therapy or during transition
from the edematous to the stable state. Clinical assessment of plasma volume may be of
particular value during treatment in patients with decompensated HF, in whom the plasma
volume is contracted despite an increase in total extracellular fluid volume. Under these
circumstances, treatment with inotropes or renal vasodilators may be more appropriate than
intravenous diuretics alone. Further studies evaluating plasma volume in HF may help to
improve our understanding of the pathophysiologic mechanisms occurring in the develop-
ment and progression of this complex condition. (J Am Coll Cardiol 2002;39:1901–8)
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It is estimated that around 60% of human tissue is made up
of water, the majority being intracellular. The extracellular
fluid volume (ECF) is composed of intravascular and
extravascular compartments. The intravascular compart-
ment is also known as the plasma volume (PV), whereas the
extravascular compartment represents fluid within the in-
terstitial space. It is possible to calculate the volumes of each
of these compartments using standard dilution techniques
with various tracer molecules. Within current clinical prac-
tice, PV measurements are used primarily in the investiga-
tion of hematologic disorders, particularly in the evaluation
of an abnormal packed cell volume. Disproportionate fluc-
tuations in PV may result in either hemoconcentration or
hemodilution, thereby influencing the measured packed cell
volume. For example, a reduction in PV will result in
hemoconcentration, giving rise to an apparent polycythemia
(“pseudopolycythemia”). Alterations in PV occur in a di-
verse array of clinical circumstances, including healthy
subjects undertaking exercise (1), in pregnancy (2), and in
pathologic conditions such as chronic anemia (3), chronic
heart failure (CHF) (4) and cirrhosis (5). After an overview
of the normal physiology of sodium and water homeostasis,
which is central to PV regulation, we will review the
methods available for the measurement of PV. Alterations
in PV that occur in patients with heart failure (HF) and
their clinical importance will then be discussed.
REGULATION OF PLASMA VOLUME
The regulation of ECF, and hence PV, is achieved by a
complicated interaction between afferent and efferent mech-
anisms (Fig. 1). Sodium is the major solute in the ECF, and
as such is a prime determinant of osmotic pressure. Therefore,
control of ECF is intimately related to sodium homeostasis.
Because excretion of sodium and water occurs primarily via the
kidney, this organ plays a pivotal role in PV regulation.
Afferent Mechanisms
Afferent sensing mechanisms and the subsequent neurohor-
monal responses are directed primarily toward the mainte-
nance of circulatory homeostasis (5–7). Low-pressure vol-
ume receptors are located mainly in the cardiac atria (8). An
increase in stretch of these receptors results in the secretion
of atrial natriuretic peptide (ANP). Stimulation of atrial
mechanoreceptors also leads to an alteration in neural
signaling to the hypothalamus and medulla, thereby influ-
encing vasopressin synthesis and release and sympathetic
nervous system (SNS) discharge to the kidneys (9).
High-pressure receptors are located in the left ventricle,
aortic arch and carotid sinus (6,10). A decrease in arterial
pressure results in the inhibition of baroreceptor discharge
and subsequent activation of the SNS and the renin-
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angiotensin-aldosterone systems and vagal withdrawal, to-
gether with the nonosmotic release of vasopressin.
Further receptors are located in the renal juxtaglomerular
apparatus (11). A decrease in renal perfusion pressure or a
reduction in tubular sodium load results in enhanced renin
release. Both the SNS and ANP further modulate renin
release (12,13).
Efferent Mechanisms
Sodium and water retention. RENIN-ANGIOTENSIN-
ALDOSTERONE SYSTEM. In the kidney, angiotensin II is a
powerful vasoconstrictor of efferent glomerular arterioles,
helping to maintain the glomerular perfusion pressure (14).
It also acts directly on renal tubular epithelial cells, increas-
ing sodium reabsorption (15). By inducing constriction of
mesangial cells, angiotensin II decreases the effective area
for filtration, further conserving sodium and water (16).
Angiotensin II also enhances the release of norepinephrine
from nerve terminals and stimulates aldosterone production
from the adrenal cortex (6,17). Aldosterone promotes the
retention of sodium in cortical collecting tubules and acti-
vates the SNS (18). The absence of escape from the actions
of aldosterone is an important feature in patients with CHF
and depends, at least in part, on decreased sodium delivery
to the collecting duct (6).
SYMPATHETIC NERVOUS SYSTEM. Stimulation by direct re-
nal sympathetic innervation and circulating catecholamines
result in an increase in renal sodium reabsorption. This is
achieved by alterations in local hemodynamics and direct
tubular effects similar to those described for angiotensin II
(14). By direct stimulation of renin production and the
subsequent activation of angiotensin II, the SNS further
enhances sodium reabsorption (19).
VASOPRESSIN. Osmotic release of vasopressin occurs in
response to an increase in extracellular osmolality sensed by
cells in the anterior hypothalamus. Nonosmotic release
results from disturbances in circulatory homeostasis de-
tected by high-pressure mechanoreceptors (10). Vasopressin
interacts with specific receptors found in the kidney, result-
ing in a net decrease in water clearance (20).
Natriuresis and diuresis. Atrial natriuretic peptide, origi-
nating in the atria, and brain natriuretic peptide, released
from the ventricular myocardium in response to wall stress
(21), are structurally related peptides with important natri-
uretic and diuretic actions (20,22). An increase in the
glomerular filtration rate arises from increased perfusion
pressure caused by afferent arteriolar vasodilation and effer-
ent arteriolar vasoconstriction (23). By relaxing mesangial
calls, natriuretic peptides increase the effective area for
filtration, an opposite effect to that of angiotensin II (24).
Natriuretic peptides also inhibit sodium reabsorption in
collecting duct cells in the inner medulla (25). Atrial
natriuretic peptide appears to have a direct effect on vascular
permeability because when infused into nephrectomized rats
still results in a fall in PV (26). Patients with CHF
demonstrate a degree of resistance to the effects of exoge-
nous ANP (more so than BNP); a decrease in distal tubular
sodium delivery seems to be implicated in this effect (6,20).
Vasodilatory prostaglandins, by counteracting
neurohormonal-induced renal vasoconstriction, also con-
tribute to sodium and water homeostasis (6). Their clinical
importance is apparent when prostaglandin production is
blocked by non-steroidal anti-inflammatory drugs, precipi-
tating the retention of fluid in patients with CHF.
The mechanisms outlined so far go only partway in
describing the complex interactions between neurohor-
monal pathways involved in salt and water balance. For
example, angiotensin II facilitates the release of ANP (27).
However, ANP is able to modulate the renal effects of
angiotensin II (28). It is the crucial interaction between the
systems described that enables normal subjects to maintain
a relatively constant PV despite alterations in sodium and
water intake (29). The importance of precise homeostasis in
normal humans is exemplified when abnormalities are seen
in diseased states such as congestive HF, where the potent
sodium and water retaining actions of angiotensin II and
aldosterone appear to overwhelm the opposing natriuretic
peptide system.
MEASUREMENT OF PLASMA VOLUME
Several methods are available for determining PV, all of
which involve the principles of dilutional analysis employed
after the administration of tracer molecules. The Interna-
tional Committee for Standardization in Hematology has
made recommendations based upon reliability, reproducibil-
ity and ease of operation in routine clinical use (30). Their
recommended method is human serum albumin labeled
with radioactive iodine (125I-HSA).
125I-HSA method. A known amount of 125I-HSA is
added to plasma prepared from the subject (30). A set
volume is then injected peripherally into the subject while
the remainder is retained to prepare a standard solution.
Blood is drawn from a different vein (usually the opposite
arm) after 10, 20 and 30 min. Radioactivity of the plasma
samples and the standard are then determined in a scintil-
lation counter. By extrapolation the radioactivity at time
zero can be calculated. Using three samples reduces the
effect of early loss of radionucleotide from the circulation on
Abbreviations and Acronyms
ANP  atrial natriuretic peptide
CHF  chronic heart failure
cpm  counts/min
ECF  extracellular fluid
HF  heart failure
125I-HSA  human serum albumin labeled with
radioactive iodine
PV  plasma volume
SNS  sympathetic nervous system
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Figure 1. A summary of neurohormonal mechanisms involved in sodium and water (and hence plasma volume) homeostasis. Although the figure separates
the sodium and water retaining systems and the opposing natriuretic and diuretic systems, considerable interaction between the individual components
occurs. ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; NO  nitric oxide; PG  vasodilatory prostaglandins.
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the derived measurement, when compared to a single
10-min sample (31). This will also allow time for adequate
mixing within the circulation. The test can be performed at
the bedside and takes just over 30 min, making it applicable
to both stable and unstable patients. Having measured the
radioactivity of the standard preparation, the PV can then
be calculated by the following equation:
Radioactivity of standard (cpm/ml) 
dilution of standard  volume injected (ml)
Radioactivity of postinjection sample
(cpm/ml, adjusted to time zero)
The use of radioactive compounds (albeit at low dose) is not
suitable for all subjects; therefore, alternative methods have
been proposed, particularly for assessments made during
pregnancy (2).
Evans blue dye dilution method. After intravenous ad-
ministration, Evans blue dye binds to albumin, and its
subsequent loss from the circulation is dependent on the
rate of loss of albumin (32). The plasma concentration of
Evans blue dye can be calculated spectrophotometrically by
determining its absorbance at a specific wavelength. This
method has limitations. For example, in turbid plasma, absor-
bance can be variable, and rapid escape from the intravascular
space, leading to an overestimation of calculated PV, may occur
(2,33). Despite these problems, this method remains useful in
pregnancy and in other situations wherein the use of radiola-
beled compounds is difficult or contraindicated.
Indocyanine green dilution method. After injection, in-
docyanine green is rapidly bound to plasma proteins before
hepatic elimination (34). This method is safe in clinical
practice (35); but the half-life of indocyanine green is short
(36), and even minor inaccuracies in sampling time can lead to
significant errors (34). Furthermore, the early sampling re-
quired by this method might not fully allow adequate mixing
within the intravascular space, particularly in clinical scenarios
associated with prolonged mixing time, such as CHF (37).
Other methods. High-molecular-weight dextran has a rel-
atively long half-life and can be coupled to fluorescent
compounds, thereby negating the need for radiolabels (38).
Indeed, van Kreel et al. (39) found that the mean difference
in PV when determined by both 125I-HSA and dextran-70
techniques was only 6%. A potential limitation has been
concern regarding allergic reactions (40).
It is possible to indirectly estimate percentage shifts in PV
without knowledge of absolute values from serial concom-
itant hemoglobin and hematocrit concentrations using the
following formula (41) (before hemoglobin or hematocrit
concentration at baseline, after  concentration after inter-
vention):





l  hematocrit (after)
l  hematocrit (before)
 100
Alternatively, PV can be measured at baseline using one
of the standard techniques and then subsequent changes
may be followed indirectly with this method.
PLASMA VOLUME IN HF
To date, there have been few studies evaluating PV alter-
ations in patients with HF. The majority of the available
data refer to subjects already receiving conventional therapy
such as diuretics and vasodilators, which may themselves
influence PV. Anand et al. (4) performed a study comparing
PV measurements in 6 patients presenting with untreated
congestive HF and 11 healthy control subjects. These
patients had significant fluid overload as evidenced by the
presence of peripheral edema, elevated jugular venous pres-
sure and ascites in three cases. Mean PV, determined by the
125I-HSA method, was on average 34% higher in patients
(57.9  2.9 ml/kg) compared with control subjects (43.2 
3.0 ml/kg, p  0.012). In patients with HF total body
excess water averaged approximately 4 l per patient. This
excess water was retained almost entirely within the extra-
cellular space, with both extravascular and PV components
increasing in approximately the same proportion (the total
ECF rose by 33% and the PV rose by 34%). This was
accompanied by the anticipated neurohormonal activation,
with the patients with HF demonstrating significantly
elevated plasma levels of norepinephrine, renin, aldosterone,
ANP, growth hormone and cortisol. The authors concluded
that in untreated edematous HF the natriuretic and vaso-
dilatory influences of peptides such as ANP were over-
whelmed by the opposing systems, leading to excess sodium
and water retention. It therefore appears that in congestive
HF underfilling of the arterial circulation occurs, despite an
expanded plasma volume, and contributes to activation of
the various neurohormonal responses. This further supports
the theory that the neurohormonal response in CHF is an
evolutionary mechanism aimed primarily at preserving ar-
terial pressure (5,6).
In contrast, Feigenbaum et al. (42) determined PV, using
the Evans blue dye technique, in 12 treated patients with
clinically stable CHF (62.8  8.2 years, New York Heart
Association functional classification 2.5  0.5, left ventric-
ular ejection fraction 31.2  9.7%, peak oxygen consump-
tion 15.2  3.3 ml/kg/min) and in 7 healthy control
subjects (71.7  5.3 years, peak oxygen consumption
26.0  6.5 ml/kg/min). All patients were taking diuretics
and angiotensin-converting-enzyme inhibitors, while eight
were on beta-blockers. Plasma volume was actually con-
tracted by approximately 23% in the treated patients with
CHF when compared with controls (34  12.9 ml/kg vs.
44.5  9.0 ml/kg, p  0.05). Therefore, it appears that
standard pharmacotherapy results in a contracted PV in
stable CHF, a concept that is in contrast to the widely held
belief that CHF is associated with long-term hypervolemia.
Although this study demonstrated the net effect of
cardiovascular medications on PV in stable CHF, few data
are available regarding the exact contributions of individual
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drug classes. Diuretics are routinely prescribed for patients
with CHF. The effect of diuretics on PV reduction has
primarily been inferred from their acute influence on central
hemodynamics (decrease in pulmonary capillary wedge
pressure and cardiac output) (43) and subsequent neurohor-
monal response (increase in plasma renin and aldosterone,
decrease in plasma ANP) (44,45), as well as their effect on
body weight (46). Studies directly measuring PV shifts have
produced conflicting results. Davidov et al. (47) demon-
strated a 25% reduction in PV following administration of
furosemide in CHF patients. In contrast, Schuster et al. (48)
showed that intravenous furosemide actually expanded PV
in critically ill patients with pulmonary edema. This was
only seen in patients who did not have a significant diuretic
response. There was no significant change in PV in the
group who experienced a marked diuresis, suggesting that
PV expands at a rate approximating to the volume removed
by diuresis. The authors speculated that these results oc-
curred secondary to furosemide-induced increases in venous
capacitance and hence reduction in capillary hydrostatic
pressure (although this effect could also result from a
reduction in adrenergic activity associated with clinical
improvement).
Whether PV is depressed in subjects receiving chronic
diuretic therapy alone is not clear; the available evidence is
conflicting and mainly relates to data obtained more than 25
years ago (49,50). In the study by Feigenbaum et al. (42), in
which all patients were well diuresed, PV was contracted.
These patients were, however, also receiving additional
cardiovascular medications.
Less information is available regarding the effect on PV of
other conventional therapies used in CHF. One might
anticipate that angiotensin-converting enzyme inhibitors
reduce PV via inhibition of the renin-angiotensin-
aldosterone axis. Intravenous enalaprilat has been shown to
reduce pulmonary artery wedge pressure and right atrial
pressure without altering systemic vascular resistance, in
keeping with PV reduction (51). Fouad et al. (52) evaluated
the effect of captopril on PV, when added to optimized
diuretic and digoxin therapy, in 19 patients with severe HF.
Despite a reduction in body weight in the first week of
treatment (presumed to be secondary to enhanced diuresis)
the average PV increased significantly (from 100.83  4.40
percent of normal to 105.37  4.43 percent of normal, p 
0.05). The authors concluded that this was indicative of
intravascular fluid shift. Plasma volume did, however, pro-
gressively decrease with longer follow-up (99.6  3.88
percent of normal at one month and 92.3  5.88 percent of
normal at six months). In contrast, Herrlin et al. (53) were
unable to demonstrate a change in PV after 12 weeks’
treatment with enalapril, when added to diuretics and
digoxin in eight subjects with moderate HF.
To our knowledge there have been no studies evaluating
the direct effect of beta-blockers or digoxin on PV in HF.
Studies have been performed following the introduction of
beta-blockers in hypertensive patients. Propanolol had no
effect on PV in either the short term (three to six weeks) or
long-term (five to six months) when used as monotherapy in
the treatment of 14 hypertensive men (54).
A recent study examined the direct effect of infused
low-dose ANP on PV and transcapillary escape of intravas-
cular albumin in normal subjects (55). Initial PV was
determined by the 125I-HSA method. Subsequent change in
PV was determined from alterations in hematocrit and
hemoglobin measured at baseline and then after 1 h. The
transcapillary escape of intravascular albumin was calculated
from the percentage fall in 125I-HSA occurring over 1 h. A
reduction in PV and an enhanced transcapillary escape of
intravascular albumin (after correction for volume change)
was seen in response to ANP. The authors noted an increase
in plasma albumin concentration and, therefore, concluded
that the primary influence of ANP was on escape of
intravascular fluid rather than albumin.
Assessment of PV has been performed in 15 patients with
severe HF undergoing left ventricular assist device implan-
tation, using the 125I-HAS method (56). No control sub-
jects were included in this study and PV measurements were
merely compared to normal reference values. Although an
improvement in cardiac function, together with reduction in
circulating neurohormones, occurred following device im-
plantation, this was not associated with a significant reduc-
tion in PV (123  20% of normal at baseline; 115  14%
eight weeks after device implantation, p  0.05). The
authors speculated that changes in PV might lag behind
other physiologic and hemodynamic changes. Whether
additional fluid volume within the device itself could influ-
ence the results remains uncertain.
In healthy people, PV does not remain static but instead
demonstrates dynamic changes under certain conditions,
such as exercise (1); PV decreases in a linear fashion when
exercise intensity increases. This is primarily the result of
fluid shift from the intravascular to the extravascular space.
Acute exercise in stable patients with CHF also results in a
reduction in PV, which is associated with an increase in
hematocrit (57). In this study of 17 patients with CHF
secondary to coronary artery disease, symptom-limited ex-
ercise resulted in an 11.10  1.22% reduction in PV. The
clinical relevance of this remains uncertain, but it has been
suggested that an increase in hematocrit may be detrimental
in patients with either ischemic heart disease or CHF by
several mechanisms, including increased myocardial work-
load and a corresponding decrease in tissue oxygen delivery
(58). Prolonged exposure to extreme altitude can also cause
salt and water retention in normal subjects to a similar
extent as that found in untreated congestive HF (59).
POTENTIAL APPLICATIONS FOR
PLASMA VOLUME EVALUATION IN CHF
Many new therapies, directed toward neurohormonal sys-
tems integral to sodium and water regulation, are under
evaluation for the treatment of CHF. It is important to
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establish what effect each therapeutic intervention has on
PV. For example, many patients with CHF have impaired
renal function, which could be further compromised by a
decrease in perfusion associated with contraction of the PV.
Hence, additional reduction in PV might not be desirable,
and indeed may actually enhance activation of neurohor-
monal systems involved in sodium and water retention.
With the associated vasoconstriction, this in turn may have
adverse effects on left ventricular performance and long-
term survival. Therefore, it may be desirable to perform an
assessment of PV as part of the clinical assessment of the
patient with CHF and combine this with neurohormonal
and cytokine profiling (60) to determine the optimal com-
bination of therapies.
Patients with decompensated HF in whom PV is con-
tracted despite an increase in total ECF present a particular
therapeutic challenge. In these circumstances monitoring
PV may facilitate the tailoring of treatment, because ino-
tropes or renal vasodilators may be more appropriate than
intravenous diuretics alone.
No data are currently available regarding the alterations
occurring in PV in response to intensified medication in
patients with edematous CHF who have presented while
already on treatment. It is likely that that significant
reductions in PV occur in this setting. Anand et al. (4)
confirmed that, when compared with healthy subjects,
relative PV is expanded by 34% in patients with decompen-
sated HF not receiving therapy. In contrast, Feigenbaum et
al. (42) showed that relative PV is contracted by 23% in
stable CHF patients when compared to controls. Although
it is not possible to directly compare these studies because
different methods were used for PV assessment (although
the PVs in the control groups were very similar at 44.5 and
43.3 ml/kg), it seems reasonable to speculate that PV could
decrease by as much as 40% following intensified treatment
for decompensated CHF (Fig. 2). (Conversely, PV might
increase by as much as 70% during an episode of decom-
pensated HF.) This is likely to have important implications
when assessing alterations in plasma concentrations of
molecules during this transition. For example, our group has
previously demonstrated that elevated plasma levels of
endotoxin (lipopolysaccharide) are seen in edematous CHF
and levels decrease after an intensified diuresis associated
with a reduction in weight of about 5 kg (61). This was
taken as support for the hypothesis that translocation of
endotoxin occurs across the edematous bowel wall and
subsequently acts as a stimulus of the immune system (62).
(In CHF immune activation is associated with an adverse
prognosis [63] and it has been suggested that it may play a
central role in the pathogenesis of this complicated syn-
drome [64].) This study (61) also confirmed that proinflam-
matory cytokines are elevated in CHF patients with periph-
eral edema. However, as with other studies (65), following
restoration of the nonedematous state cytokine levels did
not immediately return to baseline values found in stable
CHF. Although this could result from long-term activation
of monocytes or macrophages after exposure to endotoxin, it
is also likely to be influenced by marked alterations in PV.
Therefore, if as anticipated PV is reduced (perhaps by as
much as 40% after intensified medical therapy and resultant
diuresis), it is possible that the expansion of the intravascular
compartment in the edematous state leads to an underap-
preciation of the burden of circulating cytokines. When
considering a potentially toxic substance and following
patients over time, one might speculate that the absolute
circulating load is more relevant than the measured concen-
tration. A comparison of circulating levels of cytokines
(concentrations corrected for PV) would perhaps be more
fitting when comparing the edematous and nonedematous
states. We are currently undertaking studies in an attempt to
clarify this important issue.
Figure 2. Amalgamated data on plasma volume measurements from the studies by Anand et al. (4) and Feigenbaum et al. (42), as assessed by human serum
albumin labeled with radioactive iodine and Evans blue dye dilution method, respectively. Plasma volume was similar in both groups of control subjects.
There is, however, a marked difference in plasma volume when comparing stable, well-treated patients with chronic heart failure (CHF) and untreated
edematous patients in the two studies. This may reflect an increase in plasma volume in the order of 70% during an episode of decompensated heart failure.
White bar  control subjects (4); black bar  edematous patients with CHF (4); dotted bar  control subjects (42); diagonal bar  treated patients with
CHF (42).
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CONCLUSIONS
Regulation of sodium and water and hence PV is achieved
by a complex series of neurohormonal interactions. Plasma
volume determination, previously the concern of hematol-
ogy departments, is now primarily performed in the nuclear
medicine setting. This will enhance the access of this
technique to cardiologists for both clinical and research
perspectives. Although many methods are available to mea-
sure PV, the 125I-HSA technique remains the standard.
Limited data are available regarding PV measurement in
patients with HF. The available data show that PV changes
according to the clinical setting. Whereas PV appears to be
expanded in edematous subjects before therapeutic inter-
vention, it is contracted in patients with stable CHF treated
with conventional therapy. Little is known, however, of how
PV alterations relate to HF symptoms or how intensifica-
tion of conventional treatment in CHF influences PV.
The measurement of PV may well be helpful in the
clinical assessment of selected patients with CHF, thereby
enabling the tailoring of increasingly complex combinations
of therapies. Furthermore, it is important to evaluate how
newer therapies for CHF patients affect PV. It is our
contention that significant alterations of PV occur in sub-
jects undergoing intensified treatment for decompensated
CHF and that this might help to explain some of the
paradoxes encountered when evaluating changes in plasma
concentrations of various proinflammatory cytokines. More
studies are required to clarify these important questions.
Acknowledgment
We thank Justin Kirk-Bayley for his assistance with Figure 1.
Reprint requests and correspondence: Dr. Paul Kalra, Clinical
Cardiology, National Heart and Lung Institute, Dovehouse Street,
London SW3 6LY, United Kingdom. E-mail: p.kalra@ic.ac.uk.
REFERENCES
1. Senay LC, Pivarnik JM. Fluid shifts during exercise. In: Terjing RL,
editor. Exercise and Sports Sciences Review. New York, NY: Mac-
Millan Publishing Co, 1985;13:335–88.
2. Brown MA, Mitar DA, Whitworth JA. Measurement of plasma
volume in pregnancy. Clin Sci 1992;83:29–34.
3. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris
PC. Pathogenesis of oedema in chronic severe anaemia: studies of body
water and sodium, renal function, haemodynamic variables, and
plasma hormones. Br Heart J 1993;70:357–62.
4. Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris
PC. Edema of cardiac origin. Studies of body water and sodium, renal
function, hemodynamic indexes, and plasma hormones in untreated
congestive cardiac failure. Circulation 1989;80:299–305.
5. Schrier RW. Pathogenesis of sodium and water retention in high-
output and low output cardiac failure, nephrotic syndrome, cirrhosis,
and pregnancy. N Engl J Med 1988;319:1065–72.
6. Schrier RW, Abraham WT. Hormones and hemodynamics in heart
failure. N Engl J Med 1999;341:577–85.
7. Harris P. Role of arterial pressure in the oedema of heart disease.
Lancet 1988;1:1036–8.
8. Dietz JR. Release of natriuretic factor from rat heart-lung preparation
by atrial distension. Am J Physiol 1984;247:R1093–6.
9. Myers BD, Peterson C, Molina C, et al. Role of cardiac atria in the
human renal response to changing plasma volume. Am J Physiol
1988;254:F562–73.
10. Schrier RW, Berl T, Anderson RJ. Osmotic and non-osmotic control
of vasopressin release. Am J Physiol 1979;236:F321–32.
11. Davis JO, Freeman RH. Mechanisms regulating renin release. Physiol
Rev 1976;56:1–56.
12. Vander AJ, Miller R. Control of renin secretion in the dog. Am J
Physiol 1964;207:537–46.
13. Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial
natriuretic peptide inhibits renin release from juxtaglomerular cells by
a cGMP-mediated process. Proc Natl Acad Sci USA 1986;83:4769–
73.
14. Myers BD, Deen WM, Brenner BM. Effects of norepinephrine and
angiotensin II on the determinants of glomerular ultrafiltration and
proximal tubule fluid reabsorption in the rat. Circ Res 1975;37:101–
10.
15. Schuster VL, Kokko JP, Jacobson HR. Angiotensin II directly
stimulates transport in rabbit proximal convoluted tubules. J Clin
Invest 1984;73:507–15.
16. de Arriba G, Barrio V, Olivera A, Rodriguez-Puyol D, Lopez-Novoa
JM. Atrial natriuretic peptide inhibits angiotensin II-induced contrac-
tion of isolated glomeruli and cultured glomerular mesangial cells of
rats: the role of calcium. J Lab Clin Med 1988;111:466–74.
17. Zimmerman BG. Adrenergic facilitation by angiotensin: does it serve
a physiological function? Clin Sci 1981;60:343–8.
18. Weber KT. Aldosterone and spironolactone in heart failure. N Engl
J Med 1999;341:753–5.
19. Packer M. Neurohormonal interactions and adaptations in congestive
heart failure. Circulation 1988;77:721–30.
20. Kalra PR, Anker SD, Coats AJS. Water and sodium regulation in
chronic heart failure: the role of natriuretic peptides and vasopressin.
Cardiovasc Res 2001;51:495–509.
21. Lang CC, Coutie WJ, Khong TK, Choy AM, Struthers AD. Dietary
sodium loading increases plasma brain natriuretic peptide levels in
man. J Hypertens 1991;9:779–82.
22. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg HA. A rapid and
potent natriuretic response to intravenous injection of atrial myocardial
extract in rats. Life Sci 1981;28:89–94.
23. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide
causes pre-glomerular vasodilatation and post-glomerular vasocon-
striction in rat kidney. Nature 1986;324:473–6.
24. Stockand JD, Sansom SC. Regulation of filtration rate by glomerular
mesangial cells in health and diabetic renal disease. Am J Kidney Dis
1997;29:971–81.
25. Light DB, Schweibert EM, Karlson KH, Stanton BA. Atrial natri-
uretic peptide inhibits a cation channel in renal inner medullary
collecting duct cells. Science 1989;243:383–5.
26. Almeida FA, Suzuki M, Maack T. Atrial natriuretic factor increases
haematocrit and decreases the plasma volume in nephrectomized rats.
Life Sci 1986;39:1193–9.
27. Cargill RI, Coutie WJ, Lipworth BJ. The effects of angiotensin II on
circulating levels of natriuretic peptides. J Clin Pharmacol 1994;38:
139–42.
28. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits
angiotensin-stimulated proximal tubular sodium and water reabsorp-
tion. Nature 1987;326:697–8.
29. Luft FC, Rankin LI, Bloch R, et al. Cardiovascular and humoral oral
responses to extremes of sodium intake in normal black and white
men. Circulation 1979;60:697–706.
30. International Committee for Standardization in Haematology. Rec-
ommended methods for measurements of red-cell and plasma volume.
J Nucl Med 1980;21:793–800.
31. Lewis SM, Liu Yin JA. Blood volume studies. Meth Hematol
1986;14:198.
32. Gregersen MI, Rawson RA. The disappearance of T-1824 and
structurally related dyes from the blood stream. Am J Physiol 1943;
138:698–707.
33. Brans YW, Andrew DJ, Dutton EB, Schwartz CA, Carey KD.
Dilution kinetics of chemicals used for estimation of water content of
body compartments in perinatal medicine. Pediatr Res 1989;25:377–
82.
1907JACC Vol. 39, No. 12, 2002 Kalra et al.
June 19, 2002:1901–8 Plasma Volume in HF
34. Cherrick GR, Stein SW, Leevy CM, Davidson CS. Indocyanine
green: observations on its physical properties, plasma decay, and
hepatic excretion. J Clin Invest 1960;39:592–600.
35. Garski TR, Staller BJ, Hepner G, Banka VS, Finney RA, Jr. Adverse
reactions after administration of indocyanine green. JAMA 1978;240:
635.
36. Haller M, Akbulut C, Brechtelsbauer H, et al. Determination of
plasma volume with indocyanine green in man. Life Sci 1993;53:
1597–604.
37. Sekimoto M, Fukui M, Fujita K. Plasma volume estimation using
indocyanine green with biexponential regression analysis of the decay
curves. Anaesthesia 1997;52:1166–72.
38. Schroder U, Arfors KE, Tanger O. Stability of fluorescein labeled
dextrans in vivo and in vitro. Microvasc Res 1976;11:57–66.
39. van Kreel BK, van Beek E, Spaanderman MEA, Peeters LLH. A new
method for plasma volume measurements with unlabelled dextran-70
instead of 125I-labeled albumin as an indicator. Clinica Chimica Acta
1998;275:71–80.
40. Dubick MA, Wade CE. A review of the efficacy and safety of 7.5%
NaCl/6% dextran 70 in experimental animals and in humans.
J Trauma 1994;36:323–30.
41. Strauss MB, Davies RK, Rosenbaum JD, Rossmeisl EC. “Water
diuresis” produced during recumbency by the intravenous infusion of
isotonic saline solution. J Clin Invest 1951;30:862–8.
42. Feigenbaum MS, Welsch MA, Mitchell M, Vincent K, Braith RW,
Pepine CJ. Contracted plasma and blood volume in chronic heart
failure. J Am Coll Cardiol 2000;35:51–5.
43. Verma SP, Silke B, Reynolds G, Muller P, Frais MA, Taylor SH.
Immediate effects of bumetanide on systemic haemodynamics and left
ventricular volume in acute and chronic heart failure. Br J Clin
Pharmacol 1987;24:21–32.
44. Bourgoignie JJ, Catanzaro FJ, Perry HM, Jr. Renin-angiotensin-
aldosterone system during chronic thiazide therapy of benign hyper-
tension. Circulation 1968;37:27–35.
45. Lijnen P, Fagard R, Staessen J, Amery A. Hormonal effects of the
diuretic xipamide in healthy men. Cardiovasc Drugs Ther 1991;5:741–6.
46. Dormans TPJ, Gerlag PGG. Combination of high-dose furosemide
and hydrochlorothiazide in the treatment of refractory congestive heart
failure. Eur Heart J 1996;17:1867–74.
47. Davidov M, Kakaviatos N, Finnerty FA, Jr. Intravenous administra-
tion of furosemide in heart failure. JAMA 1967;200:824–9.
48. Schuster C-J, Weil MH, Besso J, Caprio M, Henning RJ. Blood
volume following diuresis induced by furosemide. Am J Med 1984;
76:585–92.
49. Conway J, Lauwers P. Hemodynamic and hypotensive effects of
long-term therapy with chlorothiazide. Circulation 1960;21:21–7.
50. Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in
essential hypertension: Evidence for persistent alteration in plasma
volume and renin activity. Circulation 1970;41:709–17.
51. Tohmo H, Karanko M, Korpilahti K. Haemodynamic effects of
enalaprilat and preload in acute severe heart failure complicating
myocardial infarction. Eur Heart J 1994;15:523–7.
52. Fouad FM, Tarazi RC, Bravo EL, Hart NJ, Castle LW, Salcedo EE.
Long-term control of congestive heart failure with captopril. Am J
Cardiol 1982;49:1489–96.
53. Herrlin B, Nyquist O, Sylven C. Induction of a reduction in haemo-
globin by enalapril in stable, moderate heart failure: a double blind
study. Br Heart J 1991;66:199–205.
54. Bauer JH. Effects of propanolol therapy on renal function and body
fluid composition. Arch Intern Med 1983;143:927–31.
55. Wijeyaratne CN, Moult PJA. The effect of alpha human atrial
natriuretic peptide on plasma volume and vascular permeability in
normotensive subjects. J Clin Endocrinol Metab 1993;76:343–6.
56. James KB, McCarthy PM, Jaalouk S, et al. Plasma volume and its
regulatory factors in congestive heart failure after implantation of
long-term left ventricular assist devices. Circulation 1996;93:1515–9.
57. Feigenbaum MS, Welsch MA, Brechue WF, Handberg-Thurmond
EM, Pollock ML, Pepine CJ. Plasma volume changes with an acute
bout of high-intensity exercise in men with chronic congestive heart
failure secondary to coronary artery disease. Am J Cardiol 1998;81:
509–13.
58. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM,
Paranandi L. Stratification of morbidity and mortality outcome by
preoperative risk factors in coronary artery bypass patients: A clinical
severity score. JAMA 1992;267:2344–8.
59. Anand IS, Chandrashekhar Y, Rao SK, et al. Body fluid compart-
ments, renal blood flow, and hormones at 6,000 m in normal subjects.
J Appl Physiol 1993;74:1234–9.
60. Anker SD, Coats AJS. Metabolic, functional, and haemodynamic
staging for CHF? Lancet 1996;348:1530–1.
61. Niebauer J, Volk H-D, Kemp M, et al. Endotoxin and immune
activation in chronic heart failure: a prospective cohort study. Lancet
1999;353:1838–42.
62. Anker SD, Egerer K, Volk HD, Kox WJ, Poole-Wilson PA, Coats
AJS. Elevated soluble CD14 receptors and altered cytokines in chronic
heart failure. Am J Cardiol 1997;79:1426–30.
63. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine
parameters and mortality in patients with chronic heart failure.
Circulation 2000;102:3060–7.
64. Sharma R, Coats AJS, Anker SD. The role of inflammatory mediators
in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int
J Cardiol 2000;72:175–86.
65. Vanderheyden M, Kersschot E, Paulus WJ. Pro-inflammatory cyto-
kines and endothelium-dependent vasodilation in the forearm: Serial
assessment in patients with congestive heart failure. Eur Heart J
1998;19:747–52.
1908 Kalra et al. JACC Vol. 39, No. 12, 2002
Plasma Volume in HF June 19, 2002:1901–8
